Peptides DB
Research-centric peptide and protocol reference hub

Research library

Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.

2255studies indexed1010with human data129registered trials1946carry a numeric findingLibrarian added 23 studies today
Showing 17 studiesSortNewest indexed
C
grade
Discovery of TL10: A Soluble and Long-Acting MC4R Agonist with Tunable Lipidation for Sustained Pharmacological Activity.
Setmelanotide · Journal of medicinal chemistry · Observational · Preclinical
TL10 shows promise as a long-acting MC4R agonist with a significantly extended half-life and potential for sustained weight loss in mice. Further studies are needed to evaluate its effects in humans.
t1/2 ≈ 33.4 h for TL10, a 34-fold increase compared to setmelanotide.
B
grade
Real-World Spinal Cord Stimulation Utilization and Implant Status: An Analysis of a Novel, Real-Time, Remote Monitoring Database.
Setmelanotide · Neuromodulation : journal of the International Neuromodulation Society · 2025 · Observational · n=493
Remote monitoring of spinal cord stimulation devices shows a high rate of usage and may improve tracking of therapy utilization and implant status.
95.1% remained implanted at a median SCS implant duration of 364 days, n=493.
B
grade
Inversed impaired osteogenic activity in children with severe obesity due to MC4R deficiency compared to LEP and LEPR deficiency
Setmelanotide · biorxiv-preprint · 2025 · Observational
Children with MC4R deficiency show higher bone formation markers compared to those with LEP and LEPR deficiencies, indicating differing impacts of genetic obesity on bone health.
Serum osteocalcin and osteopontin levels were significantly lower in subjects with LEP and LEPR biallelic variants compared to controls, p<0.001.
A
grade
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
Setmelanotide · The New England journal of medicine · 2023 · RCT · Phase 3 · n=120Top journal
Setmelanotide resulted in a significant reduction in BMI and hunger scores over 52 weeks in participants with acquired hypothalamic obesity, but the long-term implications and safety profile require further investigation.
LSM change in BMI at 52 weeks was -16.5% (95% CI, -19.3 to -13.8) with setmelanotide and 3.3% (95% CI, -0.6 to 7.2) with placebo (P<0.001)
A
grade
Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.
Setmelanotide · Annals of the American Thoracic Society · 2023 · Meta-analysis · n=123
Weight-loss medications, including setmelanotide, do not appear to increase respiratory adverse events compared to placebo, but evidence for individuals with asthma is limited.
Nasopharyngitis incidence ranged from 4.1% (95% CI: 0.7%, 9.3%; tirzepatide, 0-6 months) to over 23.7% (95% CI: 19.6%, 28.1%; liraglutide, 13-24 months).
B
grade
Developmental Trajectories of Autistic Social Traits in Youth Born Extremely Preterm.
Setmelanotide · Journal of the American Academy of Child and Adolescent Psychiatry · 2025 · Observational · n=527
The study found that autistic social traits increased significantly in youth born extremely preterm from ages 10 to 17, with most showing a worsening of social performance that correlated with lower self-esteem and health issues.
ASTs in EP youth increased an average of 19 raw points from age 10 to 17 years.
B
grade
Melanocortin-4 Receptor Regulation of Endocrine Axes and Clinical Effects of Setmelanotide.
Setmelanotide · The Journal of clinical endocrinology and metabolism · 2023 · Observational · n=58High-impact journal
Setmelanotide treatment in BBS patients resulted in a significant reduction in BMI and HbA1c over 6 months, alongside changes in various hormone levels, but the clinical implications of these findings require further investigation.
BMI reduction of 3.1 kg/m² after 6 months, n=58, p<0.001.
Showing 17 of 17